Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 1/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.48 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.47 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.47 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL964372 | 0.82 | HTT (0.56) | CHRNB2CHRNB4CHRNA3CHRNA4HTT | |
| SCHEMBL966830 | 0.82 | TDP1 (0.60) | ASAH1HTTTPSAB1TPSD1TPSG1 | |
| SCHEMBL966186 | 0.82 | HTT (0.55) | CHRNB2CHRNB4CHRNA3CHRNA4HTT | |
| SCHEMBL16804701 | 0.80 | HTT (0.62) | HTTTGM2KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL26667478 | 0.78 | FOLH1 (0.63) | HTTFOLH1TPSAB1TPSD1TPSG1 | |
| SCHEMBL26667474 | 0.78 | FOLH1 (0.63) | HTTFOLH1TPSAB1TPSD1TPSG1 | |
| SCHEMBL17261334 | 0.78 | TDP1 (0.64) | ASAH1ALDH1A1LMNA | |
| SCHEMBL15834383 | 0.78 | HTT (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4HTT | |
| SCHEMBL16804706 | 0.78 | HTT (0.62) | CHRNB2CHRNB4CHRNA3CHRNA4HTT | |
| SCHEMBL917677 | 0.77 | HTT (0.65) | HTTTGM2KEAP1NFE2L2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035004-B1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8163758-B2 | Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity | PARION SCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2035004-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | Parion Sciences, Inc. (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007146869-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | CACNA1C, CACNA1B, CACNA1G | ASAH1 944/4885CHRNB2 133/4885CHRNB4 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.